Literature DB >> 21979315

[Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis].

J R Kalden1, H Burkhardt, B Buss, U Donhauser-Gruber, U Erstling, E Gromnica-Ihle, K Karberg, T Karger, C H Kneitz, A Krause, K Krüger, H-M Lorenz, U Müller-Ladner, A Rubbert-Roth, P Steffens-Korbanka, H-P Tony, J Wendler, J Wollenhaupt, G Burmester.   

Abstract

New therapeutic principles and considerable diagnostic advances have made it possible to define different rheumatic diseases and especially rheumatoid arthritis (RA) at an early stage and by starting an early and aggressive medication a considerable proportion of patients with RA will reach the status of low disease activity or even remission. With the additional development of composite measures to estimate the disease activity of RA, it was the goal of an international working group consisting of rheumatologists and patients to develop recommendations for treating rheumatoid arthritis in a similar way as for patients with hypertension or diabetes, with the aim to achieve remission as often as possible. This treat-to-target initiative has taken off in quite a number of different countries including Germany leading to discussions on how this initiative can be integrated into the specific national healthcare systems and what possibilities would exist for its implementation. To develop strategies for an improved healthcare of people suffering from rheumatic diseases and using RA as an example, action elements and postulates were developed which will be discussed in more detail in the present manuscript.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21979315     DOI: 10.1007/s00393-011-0763-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  25 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

Authors:  Lennart T H Jacobsson; Carl Turesson; Anders Gülfe; Meliha C Kapetanovic; Ingemar F Petersson; Tore Saxne; Pierre Geborek
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

3.  Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis.

Authors:  Victoria Bejarano; Philip G Conaghan; Mark A Quinn; Benazir Saleem; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2010-07-01       Impact factor: 7.580

4.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2005-11

5.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Authors:  Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2002-04

6.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.

Authors:  Mark A Quinn; Philip G Conaghan; Philip J O'Connor; Zunaid Karim; Adam Greenstein; Andrew Brown; Clare Brown; Alexander Fraser; Stephen Jarret; Paul Emery
Journal:  Arthritis Rheum       Date:  2005-01

Review 7.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Sarah L Westlake; Alexandra N Colebatch; Janis Baird; Patrick Kiely; Mark Quinn; Ernest Choy; Andrew J K Ostor; Christopher J Edwards
Journal:  Rheumatology (Oxford)       Date:  2009-11-27       Impact factor: 7.580

8.  Survival, prognosis, and causes of death in rheumatoid arthritis.

Authors:  D M Mitchell; P W Spitz; D Y Young; D A Bloch; D J McShane; J F Fries
Journal:  Arthritis Rheum       Date:  1986-06

Review 9.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

Authors:  Monika Schoels; Rachel Knevel; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios T Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maxime Dougados; Paul Emery; Desirée van der Heijde; Tom W J Huizinga; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten de Wit; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2010-04       Impact factor: 19.103

10.  Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

Authors:  Victoria Bejarano; Mark Quinn; Philip G Conaghan; Richard Reece; Anne-Maree Keenan; David Walker; Andrew Gough; Michael Green; Dennis McGonagle; Ade Adebajo; Stephen Jarrett; Sheelagh Doherty; Lesley Hordon; Richard Melsom; Kristina Unnebrink; Hartmut Kupper; Paul Emery
Journal:  Arthritis Rheum       Date:  2008-10-15
View more
  7 in total

1.  [Physiotherapy and ergotherapy are indispensable. Concrete prescription of remedies - without recourse].

Authors:  J-M Engel
Journal:  Z Rheumatol       Date:  2012-07       Impact factor: 1.372

Review 2.  [Physiotherapy in rheumatology].

Authors:  U Lange
Journal:  Z Rheumatol       Date:  2015-10       Impact factor: 1.372

Review 3.  [Physical therapy options in rheumatic diseases: what is evidence-based?]

Authors:  U Lange; S Rehart
Journal:  Orthopade       Date:  2018-11       Impact factor: 1.087

4.  [Is treat to target compatible with health insurance and health insurance funds?].

Authors:  J Wendler; E Edelmann
Journal:  Z Rheumatol       Date:  2012-10       Impact factor: 1.372

Review 5.  [Treat to target and personalized medicine (precision medicine)].

Authors:  J Detert; G R Burmester
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

6.  Quality of care of rural rheumatoid arthritis patients in Austria.

Authors:  Rudolf Puchner; Hans Peter Brezinschek; Manfred Herold; Thomas Nothnagl; Andrea Studnicka-Benke; Josef Fritz; Burkhard F Leeb
Journal:  Wien Klin Wochenschr       Date:  2014-03-28       Impact factor: 1.704

7.  [Significance and importance of physical medicine in the context of conservative therapy for rheumatic patients].

Authors:  U Lange; S Rehart
Journal:  Orthopade       Date:  2013-10       Impact factor: 1.087

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.